Heme changes HIF-alpha, eNOS and nitrite production in HUVECs after simvastatin, HU, and ascorbic acid therapies

作者：da Guarda Caroline C; Santiago Rayra P; Pitanga Thassila N; Santana Sanzio S; Zanette Dalila L; Borges Valeria M; Goncalves Marilda S^*

来源：Microvascular Research, 2016, 106: 128-136.

DOI：10.1016/j.mvr.2016.04.002

• Endothelium
• Heme
• Simvastatin
• Hydroxyurea
• Ascorbic acid

The sickle cell disease (SCD) is a hemolytic genetic anemia characterized by free heme and hemoglobin release into intravascular spaces, with endothelial activation. Heme is a proinflammatory molecule able to directly activate vascular endothelium, thus, endothelial dysfunction and vascular disease are major chronic events described in SCD. The aim of this study was to evaluate the production of endothelial nitric oxide synthase (eNOS), nitrite and hypoxia inducible factor alpha (HIF-alpha) in HUVECs (human umbilical vein endothelial cells) activated by heme in response to simvastatin, hydroxyurea (HU), and ascorbic acid therapies. eNOS and HIF-a production were evaluated by ELISA and nitrite was measured by the Griess technique. The production of HIF-a increased when the cells were stimulated by heme (p < 0.01), while treatment with HU and simvastatin reduced the production (p < 0.01), and treatment with ascorbic acid increased HIF-1 alpha production by the cells (p < 0.01). Heme increased eNOS production, (p < 0.01) but showed a heterogeneous pattern, and the lowest concentrations of all the treatments reduced the enzyme production (p < 0.01). The nitrite production by HUVECs was enhanced by stimulation with heme (p < 0.001) and was reduced by treatment with HU (p < 0.001), ascorbic acid (p < 0.001) and simvastatin (p < 0.01). In summary, our results suggest that the hemolytic vascular microenvironment in SCD requires different therapeutic approaches to promote clinical improvement, and that a combination of therapies may be a viable strategy for treating patients.

• 出版日期2016-7